Cancer Drug Trials Show Significant Survival Gains for AstraZeneca, Genmab and Others
Recent clinical trials demonstrate that new cancer treatments from major pharmaceutical firms significantly extend patient survival times across various tumor types.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
4 publishers have covered this in 13 articles since 24 Oct 2026. Bloomberg.com published first, on 24 October at 14:30 UTC; Quartz followed 45h 26m later. The most recent article, from Bloomberg.com, appeared on 30 October at 07:10 UTC.
Outlets reporting it: Bloomberg.com (major outlet), Quartz, STAT, MedPageToday.com - medical news for physicians.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- Bloomberg.comAmgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer
- Bloomberg.comAstra’s Experimental Stomach Cancer Drug Doubled Survival Time
- Bloomberg MarketsGenmab Soars as Cancer Drug Impresses in a Late-Stage Trial
- QuartzAstraZeneca is readying its own cancer-targeting drug for regulatory approval after trial win
- QuartzAmgen's cancer drug combo cut death risk by 58% in lung cancer trial
- STATSTAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
- MedPageToday.com - medical news for physiciansLower Metastasis Risk in Very High-Risk Prostate Cancer With Intensified Treatment
- STATSTAT+: GSK sees its return to cancer starting to pay off
- MedPageToday.com - medical news for physicians'Magic Drug' Reduces Risk of Death by 44% in Lung Cancer Trial
- QuartzGSK is expecting its cancer drug clinical pipeline to nearly double in 2027
Show 3 later sources
- MedPageToday.com - medical news for physiciansTargeted Doublet Improves Survival in MET-Positive Progressive Lung Cancer
- MedPageToday.com - medical news for physiciansADC Scores 'Impressive' Survival Win in Heavily Pretreated Gastroesophageal Cancer
- Bloomberg.comAstraZeneca’s Profit Boosted by Its Blockbuster Cancer Drugs
Sources
Every article we clustered into this story. Headlines link to the publisher.
- AstraZeneca’s Profit Boosted by Its Blockbuster Cancer Drugs Bloomberg.com ·
- Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial Bloomberg Markets ·
- Astra’s Experimental Stomach Cancer Drug Doubled Survival Time Bloomberg.com ·
- Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer Bloomberg.com ·
- ADC Scores 'Impressive' Survival Win in Heavily Pretreated Gastroesophageal Cancer MedPageToday.com - medical news for physicians
- Targeted Doublet Improves Survival in MET-Positive Progressive Lung Cancer MedPageToday.com - medical news for physicians
Show 7 more sources
- GSK is expecting its cancer drug clinical pipeline to nearly double in 2027 Quartz
- 'Magic Drug' Reduces Risk of Death by 44% in Lung Cancer Trial MedPageToday.com - medical news for physicians
- STAT+: GSK sees its return to cancer starting to pay off STAT
- Lower Metastasis Risk in Very High-Risk Prostate Cancer With Intensified Treatment MedPageToday.com - medical news for physicians
- STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer STAT
- Amgen's cancer drug combo cut death risk by 58% in lung cancer trial Quartz
- AstraZeneca is readying its own cancer-targeting drug for regulatory approval after trial win Quartz
In this story
- AstraZeneca
- Genmab
- Amgen
- GSK
- Merck